- Home
- NATH vs ATXS Comparison
NATH vs ATXS Comparison
Compare NATH & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATH
- ATXS
- Stock Information
- Founded
- NATH 1916
- ATXS 2008
- Country
- NATH United States
- ATXS United States
- Employees
- NATH N/A
- ATXS N/A
- Industry
- NATH Restaurants
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- NATH Consumer Discretionary
- ATXS Health Care
- Exchange
- NATH Nasdaq
- ATXS Nasdaq
- Market Cap
- NATH 385.4M
- ATXS 401.2M
- IPO Year
- NATH N/A
- ATXS 2015
- Fundamental
- Price
- NATH $110.24
- ATXS $5.86
- Analyst Decision
- NATH
- ATXS Strong Buy
- Analyst Count
- NATH 0
- ATXS 7
- Target Price
- NATH N/A
- ATXS $32.43
- AVG Volume (30 Days)
- NATH 68.1K
- ATXS 479.1K
- Earning Date
- NATH 06-10-2025
- ATXS 08-11-2025
- Dividend Yield
- NATH 1.82%
- ATXS N/A
- EPS Growth
- NATH 22.29
- ATXS N/A
- EPS
- NATH 5.87
- ATXS N/A
- Revenue
- NATH $148,182,000.00
- ATXS N/A
- Revenue This Year
- NATH N/A
- ATXS N/A
- Revenue Next Year
- NATH N/A
- ATXS N/A
- P/E Ratio
- NATH $18.67
- ATXS N/A
- Revenue Growth
- NATH 6.91
- ATXS N/A
- 52 Week Low
- NATH $67.44
- ATXS $3.56
- 52 Week High
- NATH $118.50
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- NATH 56.67
- ATXS 62.16
- Support Level
- NATH $109.26
- ATXS $5.43
- Resistance Level
- NATH $112.90
- ATXS $5.97
- Average True Range (ATR)
- NATH 3.32
- ATXS 0.44
- MACD
- NATH -0.28
- ATXS 0.06
- Stochastic Oscillator
- NATH 43.71
- ATXS 82.37
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.